EcoDrugPlus

Fibroblast Growth Factor Receptor 3

Ensembl ID : ENSBTAG00000007164
Gene Symbol: FGFR3
27 Enzyme and pathways 5 Cross references
207 Possible Orthologues:

Fibroblast Growth Factor Receptor 4

Ensembl ID : ENSBTAG00000010543
Gene Symbol: FGFR4
26 Enzyme and pathways 5 Cross references
134 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 1

Ensembl ID : ENSBTAG00000016915
Gene Symbol: FLT1
6 Enzyme and pathways 5 Cross references
211 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 3

Ensembl ID : ENSBTAG00000018572
Gene Symbol: FLT3
21 Enzyme and pathways 5 Cross references
146 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 4

Ensembl ID : ENSBTAG00000001462
Gene Symbol: FLT4
5 Enzyme and pathways 5 Cross references
210 Possible Orthologues:

Folate Hydrolase 1b

Ensembl ID : ENSBTAG00000007397
Gene Symbol: FOLH1B
3 Enzyme and pathways 4 Cross references
223 Possible Orthologues:

Follicle Stimulating Hormone Receptor

Ensembl ID : ENSBTAG00000032424
Gene Symbol: FSHR
7 Enzyme and pathways 5 Cross references
213 Possible Orthologues:

Free Fatty Acid Receptor 1

Ensembl ID : ENSBTAG00000045806
Gene Symbol: FFAR1
17 Enzyme and pathways 5 Cross references
81 Possible Orthologues:

Free Fatty Acid Receptor 2

Ensembl ID : ENSBTAG00000006566
Gene Symbol: FFAR2
7 Enzyme and pathways 4 Cross references
351 Possible Orthologues:

Fyn Related Src Family Tyrosine Kinase

Ensembl ID : ENSBTAG00000020018
Gene Symbol: FRK
8 Enzyme and pathways 5 Cross references
229 Possible Orthologues:

Galactosidase Alpha

Ensembl ID : ENSBTAG00000019256
Gene Symbol: GLA
7 Enzyme and pathways 5 Cross references
209 Possible Orthologues:

Galectin 1

Ensembl ID : ENSBTAG00000015089
Gene Symbol: LGALS1
4 Enzyme and pathways 5 Cross references
342 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).